Abstract
AbstractTriclabendazole was introduced in the early 1980s for the treatment of
Fasciola hepatica infections in livestock. Due to its high
activity against immature flukes, it has become established as the principal
anti-fluke drug on the market. More recently, triclabendazole has been used to
treat human cases of fascioliasis and is now the drug of choice for this
infection, too. Resistance to triclabendazole was first reported in 1995 in a
field population in Australia and, since that time, resistant populations have
been identified in several countries in Europe. Parallel to the spread of
resistance has been a sharp increase in the prevalence of fascioliasis, which
has been attributed largely to climate changes. Consequently, farmers are faced
with an alarming scenario, as none of the other fasciolicides on the market
possess such high activity against the damaging immature stages of fluke. The
main aim of this review is to assess current understanding of the mechanism of
action of triclabendazole against the fluke and the mechanism by which the fluke
has become resistant to it. The use of triclabendazole against animal and human
infections is summarized and suggestions are given on ways to deal with
resistance. Gaps in the knowledge of various aspects of its use are highlighted
and this may serve to open up future research areas.
Publisher
Cambridge University Press (CUP)
Subject
Animal Science and Zoology,General Medicine,Parasitology
Reference76 articles.
1. Triclabendazole-resistant Fasciola hepatica in southwest Wales;Thomas;Veterinary Record,2000
2. Human fascioliasis treated with triclabendazole (Fasinex®) for the first time
3. The effect of albendazole and triclabendazole on colchicine binding in the liver fluke Fasciola hepatica
4. The effect of metronidazole in treating human fascioliasis;Mansour-Ghanaei;Medical Science Monitor,2003
Cited by
161 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献